The management of membranous nephropathy—an update

Fernando Caravaca-Fontán, Gema M. Fernández-Juárez, Jürgen Floege, Dimitrios Goumenos, Andreas Kronbichler, Kultigin Turkmen, Cees van Kooten, Eleni Frangou, Kate I. Stevens, Mårten Segelmark, Vladimir Tesar, Hans Joachim Anders, Annette Bruchfeld, on behalf of the Immunonephrology Working Group, an official body of the European Renal Association

Research output: Contribution to journalArticlepeer-review


In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.

Original languageEnglish
Pages (from-to)1033-1042
Number of pages10
JournalNephrology Dialysis Transplantation
Issue number6
Publication statusPublished - 2022 Jun

Subject classification (UKÄ)

  • Urology and Nephrology

Free keywords

  • calcineurin inhibitors
  • cyclophosphamide
  • membranous nephropathy
  • remission
  • rituximab


Dive into the research topics of 'The management of membranous nephropathy—an update'. Together they form a unique fingerprint.

Cite this